Bank Of America Corp Vertex Pharmaceuticals Inc Call Options Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $34.1 Million - $42.1 Million	-86,700 Reduced 89.29%	10,400 $4.87 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $8.77 Million - $9.59 Million	-21,500 Reduced 18.13%	97,100 $40.6 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $17.7 Million - $21.2 Million	51,600 Added 77.01%	118,600 $48.3 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $2.42 Million - $2.71 Million	7,700 Added 12.98%	67,000 $23.6 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $1.39 Million - $1.58 Million	4,900 Added 9.01%	59,300 $18.7 Million
Q4 2022 Feb 10, 2023	BUY	$285.76 - $321.48 $4.52 Million - $5.08 Million	15,800 Added 40.93%	54,400 $15.7 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $10.6 Million - $11.8 Million	38,600 New	38,600 $11.2 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $996,390 - $1.17 Million	4,500 Added 204.55%	6,700 $1.75 Million
Q4 2021 Feb 08, 2022	SELL	$177.01 - $223.45 $17.2 Million - $21.7 Million	-97,300 Reduced 97.79%	2,200 $483,000
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $18 Million - $20.2 Million	99,500 New	99,500 $18 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.